


Approval History of PI3K Inhibitors drughunter.com



idelalisib (Zydelig)


PI3K δ

Gilead

Jul 2014
approved for R/R
FL, R/R SLL/CLL

Mar 2016
FDA issues
safety alert

Apr 2022
voluntarily withdrawn for
R/R FL, R/R SLL



copanlisib (Aliqopa)


pan PI3K

Bayer

Nov 2017
accelerated
approval for R/R FL

Jun 2021
sNDA submitted
for iNHL

Jan 2022
sNDA voluntarily
withdrawn for iNHL




duvelisib (Copiktra)

PI3K δ/γ

Secura Bio

Sep 2018
approved for R/R SLL/CLL
and accelerated approval for FL

Dec 2021
voluntarily
withdrawn for FL




alpelisib (Piqray)

PI3K α

Novartis

May 2019
approved for HER2-negative, PIK3CA-
mutated, advanced or metastatic breast cancer

Apr 2022
accelerated
approval for PROS



umbralisib (Ukoniq)

PI3K δ + CK1 ϵ

TG Therapeutics

Feb 2021
accelerated approval
for R/R MZL, R/R FL

May 2021
BLA/sNDA submitted
for CLL/SLL

Jun 2022
voluntarily withdrawn
for all indications